MIRA Prescription drugs, Inc. MIRA on Wednesday launched knowledge demonstrating the efficacy of the oral ketamine analog, Ketamir-2, in a validated animal mannequin of diabetic neuropathy, a sort of nerve injury that may happen in diabetes sufferers.
Within the research, Kind 2 diabetes was induced in rats utilizing a high-fat eating regimen mixed with a low dose of Streptozotocin (STZ).
Therapy with Ketamir-2 led to a major discount in neuropathic ache signs, with some animals returning utterly to pre-diabetic baseline sensitivity.
- These outcomes construct upon prior preclinical research utilizing different neuropathy animal fashions, the place orally administered Ketamir-2 outperformed FDA-approved neuropathic ache medicines equivalent to pregabalin and gabapentin, demonstrating a good security profile.
- Not like conventional ketamine, Ketamir-2 doesn’t induce dissociative or psychedelic results and isn’t a substrate for P-glycoprotein, permitting for extra environment friendly penetration throughout the blood-brain barrier.
Additionally Learn: EXCLUSIVE: MIRA Prescription drugs Expands Pipeline, Enhances Worth Proposition With Improvement Of Topical Formulation For Lead Ache Therapy Candidate
Diabetic neuropathy impacts between 28% to 55% of sufferers with diabetes.
Present therapy choices are restricted, with first-line therapies equivalent to pregabalin, gabapentin, and duloxetine typically delivering solely modest symptom aid. These medicine are often related to unwanted side effects equivalent to dizziness, fatigue, cognitive impairment, and gastrointestinal discomfort. As much as 50% of sufferers fail to realize significant ache discount.
On the similar time, the demand for non-opioid therapies is rising quickly, pushed by the continuing opioid disaster and heightened regulatory scrutiny. Ketamir-2’s non-addictive profile and lack of dissociative unwanted side effects place it as a powerful candidate on this rising therapy panorama.
MIRA anticipates initiating its Section 2a trial in diabetic neuropathy by the top of 2025, with the primary human efficacy knowledge anticipated within the first half of 2026.
In parallel, the corporate is creating a topical slow-release formulation of Ketamir-2 to offer localized ache aid with minimized systemic publicity.
As well as, MIRA is actively conducting ongoing research assessing the efficacy of Ketamir-2 in fashions of post-traumatic stress dysfunction.
In March, MIRA Prescription drugs signed a binding letter of intent to accumulate SKNY Prescription drugs, Inc.
The transaction features a $5 million capital infusion of money or equal consideration into MIRA, reinforcing its monetary place and supporting the development of SKNY-1, a preclinical-stage oral drug candidate for weight reduction and smoking cessation.
Worth Motion: MIRA inventory closed at $0.89 on Tuesday.
Learn Subsequent:
Market Information and Knowledge dropped at you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
